Nasdaq

Regeneron : EYLEA HD Shows Sustained Vision Gains In Wet AMD Patients At 3 Years

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration or ...
FiercePharma

Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk

Ocular's Axpaxli is a hydrogel eye injection of Pfizer’s now off-patent kidney cancer med Inlyta that the company is positioning as a potential treatment for wet age-related macular degeneration (AMD) ...
Healio

Eylea HD comparable to Eylea for long-term wet AMD control

Please provide your email address to receive an email when new articles are posted on . Eylea HD allowed for longer treatment intervals compared with Eylea and showed similar safety and efficacy.
Insurancenewsnet.com

Regeneron’s Eylea and Genentech’s Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD

"Emerging wet AMD therapies including Fovista and abicipar pegol (Allergan/Molecular Partners) will need to be priced competitively to Eylea and Lucentis in order to garner favorable tier placement.
MedCity News

Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test

An Ocular Therapeutix drug developed for the wet form of age-related macular degeneration was better at helping patients maintain vision compared to a blockbuster Regeneron Pharmaceuticals drug that ...
Insurancenewsnet.com

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
Nasdaq

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...
FiercePharma

Ocular drafts Eylea launch architect to lead attack on Regeneron's blockbuster

David Robinson has joined Ocular Therapeutix ahead of a planned approval filing for and launch of its treatment Axpaxli for wet age-related macular degeneration. (Getty Images) Plotting a challenge to ...
ksn.com

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

TARRYTOWN, N.Y., March 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for ...
Healio

FDA approves Eylea HD dosing intervals up to 5 months for wet AMD, DME

Please provide your email address to receive an email when new articles are posted on . Eylea HD dosing intervals were extended up to every 20 weeks for patients with wet AMD and DME. The approval ...
STAT

Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...